Rubius Therapeutics Announces Webcast to Review Initial Clinical Data from Ongoing Phase 1/2 Trial of RTX-240 in Patients with Advanced Solid Tumors

Rhea-AI Summary

Rubius Therapeutics (Nasdaq: RUBY) announced plans for a press release and webcast on March 15, 2021, detailing initial clinical data from its Phase 1/2 trial of RTX-240, targeting advanced solid tumors. The call, set for 8:00 a.m. EDT, will provide insights into the progress of its innovative Red Cell Therapeutics™. This treatment aims to leverage engineered red blood cells to address cancer and autoimmune diseases.

Positive

• Announcement of initial clinical data findings from the RTX-240 trial.
• The ongoing Phase 1/2 trial indicates advancement in the development of Red Cell Therapeutics™.

Negative

• None.

CAMBRIDGE, Mass., March 12, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announced that the Company plans to issue a pre-market press release and conduct a webcast on Monday, March 15, 2021, to discuss the initial clinical data findings from the ongoing Phase 1/2 trial of RTX-240 in patients with advanced solid tumors.

The Company will host a conference call and webcast with a slide presentation at 8:00 a.m. EDT on Monday, March 15^th to discuss this update. The link to the webcast of the conference call will be posted on the Investors & Media section of the Company’s website. The update may also be accessed by dialing 1-800-289-0045 (domestic) or 1-615-622-8086 (international) five minutes prior to the start of the call and providing the passcode 1294064. An archived replay will be accessible for 90 days following the event.

About Rubius Therapeutics

Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics™. The Company’s proprietary RED PLATFORM^® was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and off-the-shelf allogeneic cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Rubius’ initial focus is to advance RCT™ product candidates for the treatment of cancer and autoimmune diseases by leveraging two distinct therapeutic modalities — potent cell-cell interaction and tolerance induction. Rubius Therapeutics was recently named among the Top Places to Work in Massachusetts by the Boston Globe, and its manufacturing site was recently named 2020 Top 5 Best Places to Work in Rhode Island among medium-sized companies by Providence Business News. For more information, visit www.rubiustx.com, follow us on Twitter or LinkedIn or like us on Facebook.

Contacts:

Investors
Elhan Webb, CFA, Vice President, Investor Relations
elhan.webb@rubiustx.com

Media
Marissa Hanify, Director, Corporate Communications
marissa.hanify@rubiustx.com

Dan Budwick, 1AB
+1 (973) 271-6085
dan@1abmedia.com

FAQ

What is the purpose of the RTX-240 trial by Rubius Therapeutics?

The RTX-240 trial aims to evaluate the safety and efficacy of a new treatment targeting advanced solid tumors.

When will the initial clinical data from the RTX-240 trial be released?

The initial clinical data will be discussed in a webcast on March 15, 2021, at 8:00 a.m. EDT.

What is Rubius Therapeutics' focus with Red Cell Therapeutics™?

Rubius Therapeutics focuses on developing engineered red blood cells to treat cancer and autoimmune diseases.

How can I access the March 15 webcast from Rubius Therapeutics?

The webcast can be accessed via the Investors & Media section of the Rubius Therapeutics website.